<DOC>
	<DOC>NCT02333760</DOC>
	<brief_summary>An open follow up study of patients enrolled in the Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with autologous CD34+ cells transduced with the w1.6_hWASP_WPRE (VSVg) lentiviral vector.</brief_summary>
	<brief_title>Gene Therapy for WAS Follow-up</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<criteria>Patients enrolled in the initial phase I/II WAS conducted in France and United Kingdom (GTG002.07 and GTG003.08). Parents, guardians or patient signed informed consent, guardians or patient signed informed consent â€¢ Parents, guardians, patients unwilling to return for the follow up study period.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>